Faculty profile

Donna Reece

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Donna Reece

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
45 publications in the last five years, latest in 2026.
Senior (last) author on 10 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2015.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

188

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Clinical Trials Network Cost Effective Analyses Innovative Diagnostics Innovative Therapy Approaches Knowledge Translation Multiple Myeloma Myeloma Patient Database Development Patient-Oriented Quality Of Life

Latest papers

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
Lancet (London, England) · 2026
Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.
Blood advances · 2026
Identification of broadly tumour-reactive γδ TCRs from multiple myeloma.
Nature · 2026

All 96 publications

Latest funding

Expediting Patient-Oriented Research in Canada: Development of Myeloma Canada Research Network (MCRN)
CIHR · 2015 · Nominated PI
$32,300

All 1 grants and awards

96 publications.

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Dimopoulos MA, Schjesvold F, Fu C, Hartley-Brown MA, Gomez C, Reece D, Mikala G, Alkharabsheh O, Parrish C, de Queiroz Crusoé E, Gálvez K, Idrobo H, White D, Gupta R, Lee C, Liu CJ, Quach H, Wang Y, Cerchione C, Forsyth C, Hungria V, Kalaskar P, Graklanov V, Ho PJ, Klaiber-Hakimi M, Kwong YL, Louzada M, Mazumder A, Miles O, Nagarajan C, Prasad SVSS, Raab MS, Varga G, von der Heyde E, Xia Z, Ochoa PA, Oriol A, Yuda J, Kuroda J, Gong J, Zhou Z, Maciag P, Yu B, Rocci A, Koo P, Katz J, Richardson PG, SUCCESSOR-2 Trial Investigators

Lancet (London, England)2026

DOI: 10.1016/s0140-6736(26)01088-3 PMID: 42289183

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Rodriguez-Otero P, Morillo D, D'Souza A, Reece D, van de Donk N, Chari A, Dholaria B, Kortüm KM, Mateos MV, Mckay JT, Rosiñol L, Sureda A, Wäsch R, Bhutani M, Weisel KC, Bahlis NJ, Vishwamitra D, Skerget S, Bakshi KK, Guo Y, Sun W, Goldberg JD, Stephenson T, Prior TJ, Vandenberk L, Lee S, Smit MD, Verona RI, Oriol A, Krishnan A

Blood advances2026

DOI: 10.1182/bloodadvances.2026020648 PMID: 42685673

Identification of broadly tumour-reactive γδ TCRs from multiple myeloma.

St Paul M, Hendrikse LD, Ying F, Snow BE, Luo P, Helke S, Smith LK, Hilal A, Abelman DD, Ramamurthy N, Nault H, Wei EN, Gold MJ, Tobin C, Lien SC, Liu Y, Zhou W, Zhang X, Nguyen D, Agbede O, Pedersen S, Eagles J, Saunders ME, Berger T, Wakeham A, Scott DS, Ly D, de Campos CB, Liang G, Zheng C, Wilson WV, Masih-Khan E, White D, McCurdy A, Louzada ML, Kotb R, Chu MP, Parkin S, Reece D, Gul E, Tiedemann R, Pugh TJ, Hirano N, Ohashi PS, Stewart AK, Trudel S, Mak TW

Nature2026

DOI: 10.1038/s41586-026-11055-9 PMID: 42749802

Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis-Requiring Severe Renal Impairment.

Sharma R, Atenafu EG, Masih-Khan E, Vohra H, Bhella S, Chen C, Kukreti V, Lancman G, Prica A, Stewart AK, Tiedemann R, Trudel S, Yang C, Reece D

European journal of haematology2026Senior author

DOI: 10.1111/ejh.70116 PMID: 41536023

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C, Mina R, Caeiro G, Kentos A, Hungria V, Reece D, Niu T, Mylin AK, Hansen CT, Teipel R, Besemer B, Dimopoulos MA, Zamagni E, Yoshihara S, Kim K, Min CK, Geerts P, Van Leeuwen-Segarceanu E, Tyczynska A, Reguera JL, Johansson M, Hansson M, Turgut M, Grey M, Sidana S, Rodriguez-Otero P, Martinez-Lopez J, Hashmi H, Carson R, Kobos R, Sun W, Lantz K, Seifert A, Briseno-Toomey D, O'Rourke L, Rubin M, Vieyra D, Kang L, Mateos MV, MajesTEC-3 Trial Investigators

The New England journal of medicine2026

DOI: 10.1056/nejmoa2514663 PMID: 41363801

Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database

Varghese J, Venner CP, Louzada M, Reece D, White D, Sharma S, Su J, Chu MP, Jimenez-Zepeda VH, McCurdy A

Clinical Lymphoma, Myeloma and Leukemia2026

DOI: 10.1016/j.clml.2025.10.019

Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database

Kaedbey R, Venner CP, Reece D, Hay K, Gul E, Su J, McCurdy A, Chu MP, Jimenez-Zepeda VH, Song K

Clinical Lymphoma, Myeloma and Leukemia2026

DOI: 10.1016/j.clml.2025.10.026

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias

Bhella S, Agbayani G, Hueniken K, Vijenthira A, Wilkin AM, Sebag M, Wang P, Hicks LK, Hay AE, Hosseini-Moghaddam SM

Blood advances2026

DOI: 10.1182/bloodadvances.2025018117

Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report

Louzada ML, Reece D, Venner CP, White D, Su J, Chu MP, Zepeda VHJ, Mccurdy A, Song K, Mian H

Blood Neoplasia2026

DOI: 10.1016/j.bneo.2026.100215

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.

Chari A, van de Donk NWCJ, Dholaria B, Weisel K, Mateos MV, Goldschmidt H, Martin TG, Morillo D, Reece D, Rodríguez-Otero P, Bhutani M, D'Souza A, Oriol A, Rosiñol L, Bahlis NJ, Vishwamitra D, Skerget S, Verona RI, Bakshi K, Kang L, Prior TJ, Vandenberk L, Tolbert J, Lee S, Smit MD, Wäsch R

Blood2025

DOI: 10.1182/blood.2025029360 PMID: 40983036

Something wrong or missing on this profile? Suggest a correction

Donna Reece

Research

Latest papers

Latest funding

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Identification of broadly tumour-reactive &#x3b3;&#x3b4; TCRs from multiple myeloma.

Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis-Requiring Severe Renal Impairment.

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database

Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias

Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.

Expediting Patient-Oriented Research in Canada: Development of Myeloma Canada Research Network (MCRN)

Frequent collaborators

Michael Sebag

Arleigh McCurdy

Suzanne Trudel

Martha Louzada

Hira Mian

Rodger Tiedemann

Alissa Visram

Xuan Li

Shelly Bolotin

Tony Mazzulli

Xiao-Yan Wen

Matthew Cheung

Deepali Kumar

Tony Reiman

James Brooks

Natasha Kekre

Natasha Kekre

Christopher Bredeson

Tara Baetz

Shahid Husain

Kevin Hay

Natasha Kekre

Shelly Bolotin

Nizar Bahlis

Curtis Cooper

Chen Wang

Tom Kouroukis

Shelly Bolotin

Amaris Karin Balitsky

Ralph Meyer

Identification of broadly tumour-reactive γδ TCRs from multiple myeloma.